Search company, investor...

Guobang Pharma

gbgcn.com

Founded Year

1996

Stage

IPO | IPO

Date of IPO

8/2/2021

About Guobang Pharma

Guobang Pharma (605507.SH) is a global, multi-variety, pharmaceutical manufacturing company with industrial chain advantages and complete elements of the industrial platform.

Headquarters Location

No. 60, Xingmei Avenue Xinchang Provincial High-tech Industrial Park

Zhejiang ,

China

Missing: Guobang Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Guobang Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Guobang Pharma News

Firms in Chinese manufacturing hub suspend operations amid COVID-19 outbreak

Dec 14, 2021

Firms in Chinese manufacturing hub suspend operations amid COVID-19 outbreak Firms in Chinese manufacturing hub suspend operations amid COVID-19 outbreak Medical workers in protective suits collect swabs from residents at a nucleic acid testing site during a third round of mass testing for COVID-19 in Zhenhai district of Ningbo, Zhejiang province, China, Dec 12, 2021. (Photo: cnsphoto via Reuters) 14 Dec 2021 12:57PM (Updated: 14 Dec 2021 01:13PM) SHANGHAI: Several companies in one of China's biggest manufacturing hubs have suspended operations as local authorities try to contain a COVID-19 outbreak, halting the production of goods from batteries to textile dyes and plastics. The coronavirus outbreak has disrupted activities in parts of Zhejiang, an eastern province with a large industrial sector, where many goods are manufactured for export. At least 20 listed companies have shut down operations in Zhejiang, as tens of thousands of citizens were placed in quarantine, some domestic flights were suspended, and several sporting events were cancelled. The outbreak in three Zhejiang cities, Ningbo, Shaoxing and Hangzhou was developing at a "relatively rapid" speed, health authorities said over the weekend. The province reported 44 locally transmitted cases with confirmed symptoms on Dec 13, official data showed on Tuesday (Dec 14), taking the total to 217 just over a week since the first case was reported on Dec 6. Prior to the current outbreak, the province had reported just one local case this year. Companies reporting suspended production on Tuesday included Zhejiang Mustang Battery Co Ltd, Guobang Pharma Ltd and textile dyes maker Zhejiang Runtu Co Ltd. Ningo-based Mustang Battery said it expected the outbreak to be brought under control very soon, and the production suspension was a temporary measure that "will not have a long-term negative impact on the company's growth." Zhejiang Runtu said all its units in the Zhejiang Shangyu Economic Development Zone, which accounts for 95 per cent of its revenue, had been halted since Dec 9 and it expected a negative impact on its fourth quarter results. They joined Ningbo Homelink Eco-Itech Co Ltd, Zhejiang Zhongxin Fluoride Materials Co Ltd, Zhejiang Jingsheng Mechanical & Electrical Co Ltd and Zhejiang Fenglong Electric Co Ltd. The companies said they halted operations after local governments in one district in Ningbo and another in Shaoxing curtailed all production bar essential manufacturing. The orders cover all companies in the affected areas, but only listed firms are required to disclose any impact on their business. More than 50,000 people have been quarantined at centralised facilities across the coastal province of 64.4 million, while a further nearly half a million people were being monitored.

Guobang Pharma Frequently Asked Questions (FAQ)

  • When was Guobang Pharma founded?

    Guobang Pharma was founded in 1996.

  • What is Guobang Pharma's latest funding round?

    Guobang Pharma's latest funding round is IPO.

  • Who are the investors of Guobang Pharma?

    Investors of Guobang Pharma include Apricot Capital, Hangshi Asset Management, Fengrong Investment, Guojun Capital, ZUIG and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.